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July 17, 2012:235–41In conclusion, we believe that this comprehensive study contributes
largely to the current knowledge on TAVI; nevertheless, it provides
insufficient evidence to establish a causal association between NOAF
and EE after TAVI. The true origins of stroke during or after a TAVI
procedure are still obscure (and most likely multifactorial). Bradford
Hill’s conclusion was, “All scientific work is liable to be upset or
modified by advancing knowledge. That does not confer upon us a
freedom to ignore the knowledge we already have, or to postpone the
action that it appears to demand at a given time” (2). Thus, we should
optimize antithrombotic treatment in these patients, but it is essential
to support the research in this field.
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Incidence, Predictive Factors,
and Prognostic Value of
New-Onset Atrial Fibrillation
After Transcatheter Aortic
Valve Implantation
The Surgeon’s Comment
The paper by Amat-Santos et al. (1) on the issue of new-onset
atrial fibrillation (NOAF) after transcatheter aortic valve implan-tation (TAVI) brings to the attention a very interesting aspect of
atrial fibrillation (AF) in the setting of severe aortic stenosis. The
authors attempted to identify risk factors for AF, a common
complication, especially after conventional aortic valve replacement
when compared to TAVI (2). Nevertheless, NOAF, in the surgical
population, comes in part from direct cardiac manipulation (as
during transapical TAVI), direct or mediated cellular stress, and
most often is cryptogenic. In this series (1) the incidence of NOAF
in the patients undergoing transapical TAVI was significantly
higher than in the patients undergoing transfemoral deployment of
the valve (80% vs.20%, respectively), and all but 1 patient were
converted into sinus rhythm by time of discharge.
These findings are very interesting and warrant a couple of
comments.
Might these patients just have paroxysmal AF, which is exac-
erbated by TAVI? Patients stratified for the transapical TAVI have
worse peripheral vascular disease and are overall a sicker patient
population (3), hence coming with worse outcomes. It is obvious
that the transapical approach is the therapeutic last line of defense,
so to speak. However, it is apparent that the numbers of patients
overall in this series (1) are too few to provide sufficient
information on incidence, prediction, and prognostic value of
NOAF. It appears that NOAF after cardiac surgery can be
addressed with antiarrhythmic drugs or molecular approaches
decreasing the accumulation and effect of free radicals (4,5). In
the present series, many patients had statin treatments and
beta-blockers on board at baseline. Therefore, a lower incidence
might have been expected—that was not seen, and this is
another argument in favor of NOAF being the first manifesta-
tion of paroxysmal AF.
Another comment is warranted in regard to the presence of
mitral regurgitation (MR). With 2.9% of patients having NOAF
and severe MR, the information on the presence of mild and/or
moderate MR, which may in turn explain the presence of enlarged
left atrias contributing to this identified risk profile, is absent.
Might MR play a role in the pathophysiology of NOAF? Further-
more, during follow-up, the freedom from AF is much lower for
the NOAF patients, even though they have been discharged in
sinus rhythm. Therefore, what underlying condition remains
present and causes AF? Is this worsening MR? Cardiac remodel-
ing? Or might NOAF be exactly that: new onset and/or first
manifestation of paroxysmal AF?
It is our opinion that more awareness must be applied to
identifying AF as an independent underlying condition. Pre-
operative workup for TAVI (and any other cardiac procedure for
that matter) should not rely only on patient history alone and
electrocardiogram, but also include at least a 24-h Holter moni-
toring to effectively screen for AF. Obviously, further data are
necessary. With that in mind, we may then provide a more tailored
approach in regard to oral anticoagulation versus double platelet
antiaggregation therapy after valve replacement. This, in turn, may
possibly lead to better outcomes.
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Reply
In response to the letter by Dr. Salinas and colleagues, we agree
that the conclusions of our study (1) regarding the relationship
between new-onset atrial fibrillation (AF) and embolic events are
limited by the low number of events, and this has been clearly
stated in the study limitations section and conclusions of our
manuscript. In these sections, we also emphasized the need for
further studies in larger series of patients. However, we believe that
the point questioning the link between the occurrence of new-
onset AF and embolic events lacks a solid scientific rationale.
Atrial fibrillation is well recognized as 1 of the main causes of
cerebrovascular embolic events, and several studies have shown an
association between new-onset AF and cerebrovascular events in
many circumstances, including cardiothoracic surgery, myocardial
infarction, and sepsis. Indeed, the occurrence of short, silent
episodes of AF has recently been associated with a higher rate of
cerebrovascular events (2). Dr. Salinas and colleagues argue that no
plausible relationship could be established in those patients having
an embolic event several days after an AF episode. To this effect,
the elegant work of Glotzer et al. (3) clearly shows an increased risk
of embolic events up to 30 days after short episodes of AF.
Furthermore, several studies demonstrated a significant delay in
the recovery of atrial function leading to an increased risk for
embolic events after AF cardioversion. This delay was even longer
in the presence of left ventricular hypertrophy and in patients with
cardioembolic risk factors leading to a high CHADS2 score (4,5),
which was the case in most patients included in our study. Also, we
showed a much higher rate of embolic events (up to 40%) in
patients with short AF episodes who did not receive anticoagula-
tion therapy, and that is another argument indirectly supporting a
potential relationship between atrial arrhythmias and embolic
events. The occurrence of stroke is a major issue in the field of
transcatheter aortic valve implantation (TAVI), and knowledge of
the mechanisms involved in such events will allow us to implement
the appropriate preventive strategies. Our work represents a very
first step in this direction, and it will be followed by a largemulticenter study (ongoing) evaluating the factors associated with
this important complication.
We read with great interest the letter from Dr. Salzberg and
colleagues regarding our work. We agree with them that the possi-
bility of new-onset AF episodes as part of prior silent paroxysmal AF
merits further evaluation. Patients undergoing TAVI nowadays
usually exhibit several comorbidities, leading to a higher risk for
the development of chronic or paroxysmal AF, and it is well known
that AF episodes may often be silent (2). As was already stated in
our manuscript, the lack of electrocardiographic monitoring stud-
ies before the TAVI procedure precluded the possibility of diag-
nosing silent paroxysmal AF episodes. This aspect would merit
further assessment in future studies. Regarding the possible asso-
ciation between the degree of mitral regurgitation and new-onset
AF, we performed a further analysis in this regard, and we did not
find any significant correlation, but that might be related to the
relatively small number of patients with severe mitral regurgitation
(n  4, 2.9%). Again, this interesting point might merit further
evaluation in future studies with a larger number of patients.
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